Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
Breast cancer
ER-high
ER-low
Estrogen receptor
Triple-negative breast cancer
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
18
03
2021
accepted:
22
06
2021
pubmed:
7
9
2021
medline:
14
10
2021
entrez:
6
9
2021
Statut:
ppublish
Résumé
To determine prevalence, clinicopathological characteristics, initial treatments, and outcomes associated with low estrogen receptor (ER)-expressing invasive breast cancer. This retrospective, non-interventional database study included patients undergoing surgery with curative intent for invasive ductal or lobular breast cancer. Patients were treated between January 2003-December 2012. Demographics, clinicopathological characteristics, initial treatments, and outcomes were abstracted from patient records. Patients were categorized using immunohistochemistry to determine ER, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) levels. ER-positive patients were subclassified as ER-low (1% to 10%) and ER-high (> 10%) according to the Allred Proportion Score. Disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method and compared among groups by log-rank test. 5930 patients were included (median follow-up, 80.9 months). Of all patients included, 117 (2.0%) had ER-low tumors: 63 (53.8%) of whom had HER2- tumors and 54 (46.2%) HER2+ tumors. Five-year DFS and OS were highest in the ER-high/HER2- cohort (94.0% and 98.6%, respectively) and lowest in the triple-negative breast cancer (TNBC; 81.3% and 90.1%) and ER-low/HER2- (85.7% and 92.1%) cohorts. Menopausal status, elevated Ki-67, higher nuclear grade, higher tumor stage, presence of lymphovascular invasion, greater regional lymph node involvement, and larger tumor size were all potential prognostic factors for shorter DFS and OS. Patients with ER-low/HER2- breast cancer had similar clinicopathological characteristics, treatments, and outcomes as patients with TNBC irrespective of disease setting. Further research is needed to understand predictive and prognostic factors associated with ER-low/HER2- disease.
Identifiants
pubmed: 34487293
doi: 10.1007/s10549-021-06309-1
pii: 10.1007/s10549-021-06309-1
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
653-663Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953. https://doi.org/10.1002/ijc.31937
doi: 10.1002/ijc.31937
pubmed: 30350310
Jung KW, Won YJ, Kong HJ, Lee ES (2019) Prediction of cancer incidence and mortality in Korea, 2019. Cancer Res Treat 51:431–437. https://doi.org/10.4143/crt.2019.139
doi: 10.4143/crt.2019.139
pubmed: 30913864
pmcid: 6473283
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge Ø, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale A-L, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752. https://doi.org/10.1038/35021093
doi: 10.1038/35021093
pubmed: 10963602
Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale A-L, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423. https://doi.org/10.1073/pnas.0932692100
doi: 10.1073/pnas.0932692100
pubmed: 12829800
pmcid: 166244
Kao KJ, Chang KM, Hsu HC, Huang AT (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11:143. https://doi.org/10.1186/1471-2407-11-143
doi: 10.1186/1471-2407-11-143
pubmed: 21501481
pmcid: 3094326
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih Ie M, Sibley P, Soletormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP (2008) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54:e11-79. https://doi.org/10.1373/clinchem.2008.105601
doi: 10.1373/clinchem.2008.105601
pubmed: 19042984
Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D (2011) Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 29:1531–1538. https://doi.org/10.1200/JCO.2010.30.3677
doi: 10.1200/JCO.2010.30.3677
pubmed: 21422407
pmcid: 3082973
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. https://doi.org/10.1016/s0140-6736(05)66544-0
doi: 10.1016/s0140-6736(05)66544-0
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684. https://doi.org/10.1056/NEJMoa052122
doi: 10.1056/NEJMoa052122
pubmed: 16236738
Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK (2014) Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 25:1004–1011. https://doi.org/10.1093/annonc/mdu053
doi: 10.1093/annonc/mdu053
pubmed: 24562447
pmcid: 3999801
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784. https://doi.org/10.1016/s0140-6736(11)60993-8
doi: 10.1016/s0140-6736(11)60993-8
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC (2020) Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists guideline update. Arch Pathol Lab Med 144:545–563. https://doi.org/10.5858/arpa.2019-0904-SA
doi: 10.5858/arpa.2019-0904-SA
pubmed: 31928354
Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM (2012) Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118:1498–1506. https://doi.org/10.1002/cncr.26431
doi: 10.1002/cncr.26431
pubmed: 21837669
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thurlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol 25:3846–3852. https://doi.org/10.1200/JCO.2007.11.9453
doi: 10.1200/JCO.2007.11.9453
pubmed: 17679725
Chen T, Zhang N, Moran MS, Su P, Haffty BG, Yang Q (2018) Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysis. Clin Breast Cancer 18:1–8. https://doi.org/10.1016/j.clbc.2017.06.005
doi: 10.1016/j.clbc.2017.06.005
pubmed: 28712925
Fitzgibbons PL, Dillon DA, Alsabeh R, Berman MA, Hayes DF, Hicks DG, Hughes KS, Nofech-Mozes S (2014) Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med 138:595–601. https://doi.org/10.5858/arpa.2013-0566-CP
doi: 10.5858/arpa.2013-0566-CP
pubmed: 24236805
Caruana D, Wei W, Martinez-Morilla S, Rimm DL, Reisenbichler ES (2020) Association between low estrogen receptor positive breast cancer and staining performance. NPJ Breast Cancer 6:5. https://doi.org/10.1038/s41523-020-0146-2
doi: 10.1038/s41523-020-0146-2
pubmed: 32047851
pmcid: 7002746
Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R (2018) Low estrogen receptor (ER)-positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease? Am J Clin Pathol 150:34–42. https://doi.org/10.1093/ajcp/aqy028
doi: 10.1093/ajcp/aqy028
pubmed: 29741562
Lovejoy LA, Turner CE, Wells JM, Shriver CD, Ellsworth RE (2020) Heritability of low ER staining/HER2-breast tumors: are we missing an opportunity for germline testing? Genes 11:1469. https://doi.org/10.3390/genes11121469
doi: 10.3390/genes11121469
pmcid: 7763582
Tajiri W, Ijichi H, Takizawa K, Koi Y, Masuda T, Ueo H, Koga C, Nakamura Y, Taguchi K, Okamoto M, Tokunaga E (2021) The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer 28:67–74. https://doi.org/10.1007/s12282-020-01130-y
doi: 10.1007/s12282-020-01130-y
pubmed: 32601800
Prabhu JS, Korlimarla A, Desai K, Alexander A, Raghavan R, Anupama C, Dendukuri N, Manjunath S, Correa M, Raman N, Kalamdani A, Prasad M, Gopinath KS, Srinath BS, Sridhar TS (2014) A majority of low (1–10%) ER positive breast cancers behave like hormone receptor negative tumors. J Cancer 5:156–165. https://doi.org/10.7150/jca.7668
doi: 10.7150/jca.7668
pubmed: 24563670
pmcid: 3930907
Nishimura R, Osako T, Nishiyama Y, Okumura Y, Fujisue M, Toyozumi Y, Arima N (2017) Biology and prognosis of HER2-negative breast cancer with low-ER and PgR-expressions. J Clin Oncol 35:e12020–e12020. https://doi.org/10.1200/JCO.2017.35.15_suppl.e12020
doi: 10.1200/JCO.2017.35.15_suppl.e12020
National Comprehensive Cancer Network (NCCN) (2021) The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 1.2021. https://www.nccn.org . Accessed 26 Jan 2021
Korean Breast Cancer Society (2019) 2019 the 8th Korean Clinical Practice Guideline for Breast Cancer. http://www.kbcs.or.kr/journal/file/190513.pdf . Accessed 3 Aug 2021
Vu Hong T, Nguyen Ba D, Skoog L, Ta Thanh V, Tani E (2019) Breast cancer survival defined by biological receptor and menopausal status in Vietnamese women. Cancer Control 26:1073274819865279. https://doi.org/10.1177/1073274819865279
doi: 10.1177/1073274819865279
pubmed: 31343899
pmcid: 6659192
Tashima R, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Nakano M, Fujisue M, Toyozumi Y, Arima N (2015) Evaluation of an optimal cut-off point for the Ki-67 index as a prognostic factor in primary breast cancer: a retrospective study. PLoS ONE 10:e0119565. https://doi.org/10.1371/journal.pone.0119565
doi: 10.1371/journal.pone.0119565
pubmed: 26177501
pmcid: 4503758
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502. https://doi.org/10.1001/jama.295.21.2492
doi: 10.1001/jama.295.21.2492
pubmed: 16757721
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623–1649. https://doi.org/10.1016/j.annonc.2020.09.010
doi: 10.1016/j.annonc.2020.09.010
pubmed: 32979513